A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

NCT07147348 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

BIOLOGICAL: BNT3212
BIOLOGICAL: Pumitamig

Sponsor

BioNTech SE

Collaborators

[object Object]
[object Object]